A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Group Launches Study for Post-Marketing Safety Measures to Boost Global Harmonization, Efficiency
September 1, 2021
-
REGULATORY MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
-
REGULATORY MHLW Discussing Mandatory Reporting System for Unstable Drug Supplies
August 30, 2021
-
BUSINESS Medical Societies Issue Joint Statement in Face of Possible Stockout of Abraxane, Calling for Continued Treatment
August 30, 2021
-
BUSINESS Nippon Shinyaku Aims to Maximize Value of Viltepso, Double Sales, Operating Profits in 10 Years: President
August 27, 2021
-
BUSINESS Chugai to File Antibody Cocktail for COVID-19 Prevention among Close Contact Individuals
August 27, 2021
-
REGULATORY Japan Approves Forxiga for CKD, Rinvoq’s Atopic Dermatitis Use and More
August 26, 2021
-
BUSINESS ASKA to Accelerate Innovative Pharma Biz, Not Generics; President Sees Trivial Impact from Follow-On Blopress AG
August 25, 2021
-
REGULATORY Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
-
ORGANIZATION EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
-
BUSINESS Drug Makers’ Q1 Operating Profits Eclipsing Projections on One-Time Gains, Product Growth
August 24, 2021
-
REGULATORY PAFSC to Review Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug and More
August 24, 2021
-
REGULATORY Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
-
REGULATORY New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
August 23, 2021
-
REGULATORY Sharp Drop in Suspected Violations Seen in FY2020 Drug Promotion, but Comparison Difficult due to COVID-19: MHLW
August 23, 2021
-
ORGANIZATION New Established Drugs’ Group Places Top Priority on Stable Generic Supply; Research-Driven and Foreign Firms to Join
August 20, 2021
-
BUSINESS Yamasa Ramps Up API CMO Biz for Oligonucleotides, mRNA Drugs amid Changes in Modalities
August 19, 2021
-
BUSINESS Choseido Likely to Face Administrative Penalty over Manufacturing Flaws
August 18, 2021
-
BUSINESS Japan Pharma Market Delivers 1st Growth in 5 Qtrs in April-June: IQVIA
August 18, 2021
-
REGULATORY 14 Firms Flock to Get Approval for E Keppra Generics towards December Listing
August 17, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…